Novo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the company’s sustainable fuels and chemicals platform
German researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy.

SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.

Pieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors.

Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.

Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3.

Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.

Every year, drug developers lose billions of euros because of late-stage clinical or postmarking safety problems with drugs. A recently kicked-off IMI consortium now wants to qualify a set of safety biomarkers that allow for the prediction of drug-induced injury of kidney, liver, vasculature, CNS, and pancreas. European Biotechnology spoke with Dr Michael Merz, the coordinator of the TransBioLine Project, and consortium member Prof Dr Stefan Wnendt about the plans and impact of the project.

Plant protection specialist AgroSavfe will use the funds of a €35m Series C financing to push the development, registration and commercial scale production of its biofungicides and bio-insecticide.

The European Commission has authorised ten genetically modified products.